Antidiabetic

Divy Tradelink offers a range of antidiabetic pharmaceuticals for global export, including Mounjaro (Tirzepatide) from Eli Lilly & Company India, available across multiple strengths (2.5mg–15mg) in both KwikPen and injection formats. Sourced directly from licensed manufacturers, our antidiabetic products meet international quality and regulatory standards for reliable supply to importers and distributors worldwide.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, a newer class of medication that works by mimicking two natural gut hormones involved in blood sugar regulation. It helps the body produce more insulin when blood sugar is high, slows stomach emptying to reduce post-meal glucose spikes, and reduces appetite — making it effective for managing type 2 diabetes while also supporting weight management as an additional clinical benefit.

Mounjaro is administered once weekly via a pre-filled injection pen, with treatment typically starting at a low dose (2.5mg) and gradually increased over several weeks to the target maintenance dose based on individual response and tolerability. This dose-escalation approach helps minimize common gastrointestinal side effects such as nausea, which tend to improve as the body adjusts to treatment.

As global demand for GLP-1/GIP-based diabetes and weight management therapies continues to rise, Divy Tradelink is committed to providing a reliable, well-documented supply chain for this in-demand medication. All Mounjaro KwikPens and injections we supply come with complete manufacturer documentation, batch traceability, and cold-chain handling support to maintain product integrity throughout international shipping.

For bulk order inquiries, specific dose availability, or questions about cold-chain logistics and import documentation for your country, our team at Divy Tradelink is ready to assist with pricing and export support tailored to your requirements.